SCHEMBL76546

SCHEMBL76546

CCN(CC)CC(=O)N(CC)c1ccc(N)c(N)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100B P04271 1/20 0.37
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
ALDH1A1 P00352 5/20 0.35
TSHR P16473 2/20 0.35
GLA P06280 1/20 0.35
CYP3A4 P08684 2/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA4 P22748 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
AGTR1 P30556 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KCNH2 Q12809 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
SCN3A Q9NY46 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL77877 0.82 LMNA (0.43) ALDH1A1TSHRCYP3A4MAPTMEN1
SCHEMBL6325187 0.69 ALDH1A1 (0.46) ALDH1A1TSHRCYP3A4CA12CA1
SCHEMBL78475 0.69 ALDH1A1 (0.59) ALDH1A1CYP3A4KDM4EMAPTMEN1
SCHEMBL11431090 0.68 S100B (0.70) S100BALDH1A1TSHRGLACYP3A4
SCHEMBL27379028 0.68 S100B (0.59) S100BALDH1A1TSHRGLACYP3A4
SCHEMBL9135996 0.68 TDP1 (0.44) S100BALDH1A1TSHRGLACYP3A4
SCHEMBL11286380 0.68 TDP1 (0.44) S100BALDH1A1TSHRGLACYP3A4
SCHEMBL2811318 0.67 GAA (0.54) ALDH1A1TSHRGLACYP3A4KDM4E
SCHEMBL15938563 0.67 KDM4E (0.44) S100BMAPK8ALDH1A1TSHRGLA
SCHEMBL14116544 0.67 SMN1; SMN2 (0.41) S100BALDH1A1TSHRGLACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129396-B2 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. (US) 2012-03-06 US disclosed
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors MAP3K2, MAP4K2, MAP3K12 S100B 4409/4885MAPK8 143/4885MAPK9 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.